• Ridaforolimus and the Next mTOR Research Frontier

  2026-09-03

  Ridaforolimus, also known as Deforolimus or MK-8669, provides a highly potent framework for interrogating mTOR-dependent growth, translation, metabolism, and angiogenic signaling. Combined with machine-learning approaches to senolytic discovery, it supports a more disciplined translational strategy: separate pathway engagement from cell-state selectivity, validate both with orthogonal assays, and advance only the most reproducible biological hypotheses.

• Halazone: From Chloramine Chemistry to Assay Design

  2026-09-03

  Halazone is an antimicrobial sulfonamide derivative with a practical dual identity: a water disinfection agent and an oxidant that alters neuronal sodium-current inactivation. This assay-focused guide explains how concentration, redox conditions, formulation stability, and voltage-clamp design determine interpretable results.

• Mubritinib (TAK 165): Beyond HER2

  2026-09-02

  Mubritinib (TAK 165) is best understood as a mitochondrial complex I probe rather than a conventional HER2 inhibitor. This article explains how that mechanistic reclassification improves AML, PEL, OXPHOS, apoptosis, and translational assay design.

• Anlotinib Hydrochloride: From Assay to Evidence

  2026-09-02

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor whose anti-angiogenic activity can be interpreted more rigorously by connecting receptor pharmacology, endothelial phenotypes, pharmacokinetics, and translational evidence. This article presents an assay-to-evidence framework for cancer research while clarifying what a single case report can—and cannot—establish.

• Isochlorogenic Acid A Targets RIP3 in Cardiac Hypertrophy

  2026-09-01

  A 2026 Cellular Signalling study identifies isochlorogenic acid A as a direct regulator of RIP3 in angiotensin II- and pressure overload-induced cardiac hypertrophy. Its findings connect RIP3 to CaMKII activation independently of MLKL, providing a mechanistic basis for studying maladaptive remodeling and a potential framework for pathway-focused cardiovascular disease research.

• Irinotecan (CPT-11): Mechanism and Research Use

  2026-09-01

  Irinotecan, also called CPT-11, is a carboxylesterase-activated topoisomerase I inhibitor used to model DNA damage, apoptosis, and colorectal cancer biology. Product and peer-reviewed evidence support its use in cell-based cytotoxicity studies, xenograft experiments, and investigations of chemotherapy-associated gut–liver toxicity.

• MPA at the Reproductive Signaling Frontier

  2026-08-31

  Medroxyprogesterone acetate is more than a conventional progestin tool: its progesterone receptor activity, glucocorticoid receptor engagement, and context-dependent epithelial and neural effects make it a strategic probe for translational biology. This article connects MPA research with recent findings on endometrial stromal cell senescence, R-loop resolution, and decidualization while outlining a disciplined path from mechanistic discovery to reproducible model development.

• CDK4/6–BET Synergy in Pancreatic Cancer

  2026-08-31

  Gu et al. show that combining the CDK4/6 inhibitor palbociclib with the BET inhibitor JQ1 can suppress pancreatic ductal adenocarcinoma while counteracting the epithelial-to-mesenchymal transition associated with CDK4/6 inhibition alone. The study links this effect to GSK3β-mediated Wnt/β-catenin signaling and its crosstalk with TGF-β/Smad pathways, providing a mechanistic rationale for combination treatment.

• MLF2, USP7, and p53 in Colorectal Cancer

  2026-08-30

  The reference study identifies myeloid leukemia factor 2 (MLF2) as a negative regulator of p53 that interferes with USP7-mediated p53 deubiquitination and destabilizes p53. Its integrated molecular, functional, and clinical evidence connects elevated MLF2 with colorectal cancer progression and poor prognosis, while also highlighting the importance of preserving protein integrity during validation assays.

• Sequencing Therapy in Waldenström Macroglobulinemia

  2026-08-29

  The 2021 review by Sarosiek, Treon, and Castillo proposes a genomically informed framework for sequencing Waldenström macroglobulinemia therapy rather than treating regimen selection as a fixed algorithm. Its practical contribution is to integrate MYD88 and CXCR4 status with disease urgency, comorbidities, toxicity expectations, patient preferences, and the limited comparative evidence available in this rare malignancy.

• Arachidonic Acid and Rapid Vaccine Immunity

  2026-08-28

  The reference study shows that dietary arachidonic acid (ARA) can accelerate and strengthen rabies vaccine-induced neutralizing antibody responses in mice and human volunteers. Its mechanistic contribution is a lymph-node-centered model in which ARA-derived prostaglandin I2 engages cAMP–PKA signaling to enhance CD86 expression and activation-induced cytidine deaminase in B cells.

• L-Alanyl-L-Glutamine: Practical Research Guide

  2026-08-28

  L-Alanyl-L-Glutamine (SKU B8228) provides a water-soluble L-Ala-L-Gln dipeptide for GI barrier, nutritional, and catabolic-stress workflows where aqueous preparation is appropriate. It should not be selected for DMSO- or ethanol-based protocols, and aqueous solutions should not be stored long term.

• Acquired CDK7 Mutation Drives Drug Resistance

  2026-08-27

  The reference study identifies CDK7 D97N as an acquired mutation that selectively reduces sensitivity to non-covalent CDK7 inhibitors while preserving sensitivity to covalent compounds. Structural, affinity, and cross-kinase experiments indicate that mutation of this conserved residue may represent a broader mechanism of resistance across cyclin-dependent kinase therapies.

• Ceftolozane/Tazobactam: Evidence and Research Implications

  2026-08-27

  This 2015 review evaluates ceftolozane/tazobactam as an antipseudomonal cephalosporin/β-lactamase inhibitor combination, integrating its mechanism, resistance profile, pharmacokinetics, pharmacodynamics, clinical evidence, and tolerability. Its main contribution is a practical framework for interpreting activity against difficult Gram-negative pathogens while recognizing renal dosing requirements and the limits of extrapolating in vitro or early clinical findings.

• Medroxyprogesterone Acetate: Research Workflows

  2026-08-26

  Build reproducible MPA experiments for progesterone signaling, renal epithelial biology, reproductive models, and neurobiology. This workflow emphasizes solvent control, receptor-aware interpretation, and practical translation of a recent endometrial senescence study into assay design.

8620 records 1/575 page Next 12345 下5页 Last page